Wertli, Maria M.; Held, Ulrike; Signorell, Andri; Steurer, Johann; Blozik, Eva; Burgstaller, Jakob M (2019). Opioid Prescription in Switzerland: Appropriate Comedication use in Cancer and Noncancer Pain. Pain physician, 22(6), pp. 537-548. American Society of Interventional Pain Physicians
Text
Wertli, Pain Physician 2019.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (236kB) |
BACKGROUND
In Europe, limited information on the use of opioids is available.
OBJECTIVES
To assess how guideline recommendations to manage opioid-related adverse events were followed in cancer- and noncancer-related opioid use.
STUDY DESIGN
Analysis of health insurance data of one of the major health insurers in Switzerland.
SETTING
All opioid claims between 2006 and 2014.
METHODS
Opioid episodes were cancer-related when cancer treatments were used within ± 3 months of the first opioid claim. Recurrent strong episodes were defined as >/= 2 opioid claims with at least one strong opioid claim. Episode duration were acute (< 90 days), subacute, or chronic (>/= 120 days >/= 90 days +>/= 10 claims).
RESULTS
Out of 591,633 opioid episodes 76,968 (13%) were recurrent episodes: 94% were noncancer related (83% in recurrent episodes) and 6% cancer related (17% recurrent). Chronic opioid use was observed in 55% (noncancer) and 58% (cancer) recurrent episodes. Recommended laxatives were used in 50% noncancer and in 67% cancer episodes. Antiemetic drugs were used in 54% noncancer and in 83% cancer episodes. Not recommended coprescription of benzodiazepines was observed in 34% recurrent noncancer and 46% cancer episodes.
LIMITATIONS
No clinical information was available to assess the indication for opioid use.
CONCLUSIONS
In this study, opioids were primarily used outside the context of cancer-related treatment. In noncancer-related opioid use, we found a substantial higher proportion without recommended laxative and antiemetic medications. Coprescription of benzodiazepines may increase the risk for opioid overdose and was present in one-third of the noncancer episodes and in almost every second cancer episode.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine |
UniBE Contributor: |
Wertli, Maria Monika |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1533-3159 |
Publisher: |
American Society of Interventional Pain Physicians |
Language: |
English |
Submitter: |
Tobias Tritschler |
Date Deposited: |
16 Dec 2019 15:01 |
Last Modified: |
05 Dec 2022 15:33 |
PubMed ID: |
31775398 |
Uncontrolled Keywords: |
Pain medications, opioids, nonopioids, benzodiazepines, health insurance claims data, cancer pain, noncancer pain, chronic opioid use, adverse events prevention, guideline recommendations. |
BORIS DOI: |
10.7892/boris.136027 |
URI: |
https://boris.unibe.ch/id/eprint/136027 |